ArticleFrontiers in immunology2020

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.

Paal F Brunsvig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.